Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey.
adverse effects
ayahuasca
mental health
psychedelic therapy
set and setting
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
10
2020
accepted:
22
02
2021
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
epublish
Résumé
Ayahuasca is a traditional plant decoction containing N,N-dimethyltryptamine (DMT) and various β-carbolines including harmine, harmaline, and tetrahydroharmine, which has been used ceremonially by Amazonian Indigenous groups for healing and spiritual purposes. Use of the brew has now spread far beyond its original context of consumption to North America, Europe, and Australia in neo-shamanic settings as well as Christian syncretic churches. While these groups have established their own rituals and protocols to guide use, it remains unknown the extent to which the use of traditional or non-traditional practices may affect drinkers' acute experiences, and longer term wellbeing and mental health outcomes. Hence, this study aimed to provide the first detailed assessment of associations between ceremony/ritual characteristics, additional support practices, motivations for drinking, and mental health and wellbeing outcomes. The paper uses data from a large cross-sectional study of ayahuasca drinkers in more than 40 countries who had used ayahuasca in various contexts (
Identifiants
pubmed: 33967757
doi: 10.3389/fphar.2021.623979
pii: 623979
pmc: PMC8097729
doi:
Types de publication
Journal Article
Langues
eng
Pagination
623979Informations de copyright
Copyright © 2021 Perkins, Schubert, Simonová, Tófoli, Bouso, Horák, Galvão-Coelho and Sarris.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pharmacol Ther. 2004 May;102(2):111-29
pubmed: 15163593
PLoS One. 2017 Aug 15;12(8):e0181305
pubmed: 28809923
Psychopharmacology (Berl). 2006 May;186(1):93-8
pubmed: 16575552
J Nerv Ment Dis. 1963 Dec;137:561-73
pubmed: 14087676
Psychosomatics. 2009 Nov-Dec;50(6):613-21
pubmed: 19996233
J Psychoactive Drugs. 1989 Jan-Mar;21(1):77-89
pubmed: 2656954
Arch Gen Psychiatry. 2003 Feb;60(2):184-9
pubmed: 12578436
Int J Methods Psychiatr Res. 2019 Dec;28(4):e1801
pubmed: 31568635
J Psychoactive Drugs. 2020 Nov-Dec;52(5):472-481
pubmed: 32748709
Health Qual Life Outcomes. 2020 Mar 30;18(1):83
pubmed: 32228598
J Manipulative Physiol Ther. 2004 Jan;27(1):26-35
pubmed: 14739871
Soc Sci Med. 2011 Oct;73(8):1222-9
pubmed: 21880408
Front Pharmacol. 2018 Nov 02;9:897
pubmed: 30450045
Compr Psychiatry. 2016 Nov;71:95-105
pubmed: 27653781
Psychopharmacology (Berl). 2018 Oct;235(10):2979-2989
pubmed: 30105399
J Psychoactive Drugs. 2020 Apr-Jun;52(2):130-137
pubmed: 31570056
Med Sci Monit. 2008 Aug;14(8):SR15-22
pubmed: 18668010
J Psychoactive Drugs. 2021 Jan-Mar;53(1):65-75
pubmed: 32896230
Hum Psychopharmacol. 2020 May;35(3):e2728
pubmed: 32220028
Biol Trace Elem Res. 2021 Mar;199(3):1179-1184
pubmed: 32504397
Sci Rep. 2020 Mar 5;10(1):4075
pubmed: 32139811
Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92
pubmed: 16826400
Drug Alcohol Depend. 2010 Sep 1;111(1-2):30-7
pubmed: 20570058
PLoS One. 2012;7(8):e42421
pubmed: 22905130
Epilepsy Behav. 2019 Jun 7;:106300
pubmed: 31182391
PLoS One. 2019 Apr 23;14(4):e0214377
pubmed: 31013281
CNS Drugs. 2020 Sep;34(9):925-946
pubmed: 32803732
J Psychopharmacol. 2016 Dec;30(12):1259-1267
pubmed: 27852960